Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Keep reading to learn which According to a report by 'Rolling Stone,' the former model and author was allegedly forced by ...
MPS offers to cover part of SROs' salaries, training costs ahead of Feb. 17 deadline ...
Raw Story on MSN4h
Cabinet member's kid took life-changing drug — but he's now 'shutting that door': reportThe daughter of a key architect of Project 2025 benefitted from a life-changing drug — which was created with the help of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback